Allergan receives approval for its migraine drug Ubrelvy from FDA
Category: #health  By Pankaj Singh  Date: 2019-12-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Allergan receives approval for its migraine drug Ubrelvy from FDA

Allergan, a renowned multinational biopharmaceutical company, has been awarded approval for its oral CGRP (calcitonin gene-related peptide) medicine for the treatment of migraines. The field of CGRP migraine prevention already contains three medicines, from Eli Lilly, Amgen and Teva, competing for a chunk of the market share.

The medication, Ubrelvy, previously known as ubrogepant, received FDA approval, becoming the first ever oral CGRP medicine for the treatment of migraines. The company’s medicine is considered to be an effective treatment for migraine without or with aura, referring to the visual or sensory disturbances that usually occur in roughly a third of migraine sufferers.

The med is expected to face competition from rimegepant, developed by Biohaven, by 2020. Allergan is planning to launch the drug by the first quarter (Q1) next year.

Peter Goadsby, neurologist and professor, King’s College, reportedly stated that during clinical trials the medication provided pain relief to a majority of participants as compared to placebo. The drug has also helped give relief from other symptoms like sound and light sensitivity and nausea.

The analysts from EvaluatePharma have made a prediction that by 2024 the drug would likely generate $302 million in revenues.

The field of migraine saw a surge in activity due to three CGRP approvals in last year along with corresponding launches. Although Eli Lilly had lately been gaining steam with its Emgality, Amgen lead the market with its Aimovig medication.

Eli Lilly scored approval from FDA for Emgality to address cluster headaches and for Reyvow, a new migraine treatment. The firm is expecting to launch Reyvow by early 2020 following a DEA scheduling.

Additionally, Allergan will be combining with AbbVie by next year as part of a merger, the two companies will sign the agreement in June.

The American Migraine Foundation stated that an estimate of 40 million Americans and 1 billion people across the world suffer from migraines. It is likely to affect one in five women and one in 16 men.

Source credit: https://www.fiercepharma.com/pharma/allergan-scores-year-end-fda-nod-for-cgrp-migraine-med-ubrelvy-plans-early-2020-launch



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...